Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone416-595-0627
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/13/2019 (Estimated)
OptionableOptionable
Trillium Therapeutics (NASDAQ:TRIL) Frequently Asked Questions
What is Trillium Therapeutics' stock symbol?
Trillium Therapeutics trades on the NASDAQ under the ticker symbol "TRIL."
How were Trillium Therapeutics' earnings last quarter?
Trillium Therapeutics Inc (NASDAQ:TRIL) issued its earnings results on Friday, May, 11th. The biotechnology company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.13. View Trillium Therapeutics' Earnings History.
When is Trillium Therapeutics' next earnings date?
What price target have analysts set for TRIL?
2 Wall Street analysts have issued 1 year price objectives for Trillium Therapeutics' stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Trillium Therapeutics' stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 1,154.3% from the stock's current price. View Analyst Price Targets for Trillium Therapeutics.
What is the consensus analysts' recommendation for Trillium Therapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trillium Therapeutics.
Has Trillium Therapeutics been receiving favorable news coverage?
News coverage about TRIL stock has trended positive recently, InfoTrie reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Trillium Therapeutics earned a coverage optimism score of 2.5 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the next few days. View News Stories for Trillium Therapeutics.
Who are some of Trillium Therapeutics' key competitors?
Some companies that are related to Trillium Therapeutics include Teligent (TLGT), Leap Therapeutics (LPTX), Proteostasis Therapeutics (PTI), Bio-Path (BPTH), Vital Therapies (VTL), Aptevo Therapeutics (APVO), Melinta Therapeutics (MLNT), AEterna Zentaris (AEZS), Alimera Sciences (ALIM), Sierra Oncology (SRRA), Zafgen (ZFGN), Innovate Biopharmaceuticals (INNT), ContraFect (CFRX), DiaMedica Therapeutics (DMAC) and AzurRx BioPharma (AZRX).
What other stocks do shareholders of Trillium Therapeutics own?
Who are Trillium Therapeutics' key executives?
Trillium Therapeutics' management team includes the folowing people:
- Dr. Bjorn Johan Niclas Stiernholm, Pres, CEO & Director
- Mr. James T. Parsons C.A., C.P.A., MAcc, CPA-CA, Chief Financial Officer (Age 54)
- Dr. Robert Uger, Chief Scientific Officer
- Dr. Penka Petrova, Chief Devel. Officer
- Dr. Yaping Shou, Chief Medical Officer
Who are Trillium Therapeutics' major shareholders?
Trillium Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Morgan Stanley (3.73%).
Which major investors are buying Trillium Therapeutics stock?
TRIL stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley.
How do I buy shares of Trillium Therapeutics?
Shares of TRIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Trillium Therapeutics' stock price today?
One share of TRIL stock can currently be purchased for approximately $0.3189.
How big of a company is Trillium Therapeutics?
What is Trillium Therapeutics' official website?
How can I contact Trillium Therapeutics?
Trillium Therapeutics' mailing address is 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9. The biotechnology company can be reached via phone at 416-595-0627 or via email at [email protected]
MarketBeat Community Rating for Trillium Therapeutics (NASDAQ TRIL)
MarketBeat's community ratings are surveys of what our community members think about Trillium Therapeutics and other stocks. Vote "Outperform" if you believe TRIL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRIL will underperform the S&P 500 over the long term. You may vote once every thirty days.
